KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Intangibles (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Intangibles for 3 consecutive years, with $401.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Intangibles fell 15.02% to $401.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $401.8 million, a 15.02% decrease, with the full-year FY2024 number at $401.8 million, down 15.02% from a year prior.
  • Intangibles was $401.8 million for Q4 2024 at Halozyme Therapeutics, down from $472.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $546.7 million in Q4 2022 to a low of $401.8 million in Q4 2024.
  • A 3-year average of $473.8 million and a median of $472.9 million in 2023 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: fell 13.5% in 2023, then dropped 15.02% in 2024.
  • Halozyme Therapeutics' Intangibles stood at $546.7 million in 2022, then dropped by 13.5% to $472.9 million in 2023, then fell by 15.02% to $401.8 million in 2024.
  • Per Business Quant, the three most recent readings for HALO's Intangibles are $401.8 million (Q4 2024), $472.9 million (Q4 2023), and $546.7 million (Q4 2022).